Current evidence on screening for renal cancer
Renal cell carcinoma (RCC) incidence is increasing worldwide. A high proportion of individuals are asymptomatic at diagnosis, but RCC has a high mortality rate. These facts suggest that RCC meets some of the criteria for screening, and a new analysis shows that screening for RCC could potentially be...
Gespeichert in:
| Veröffentlicht in: | Nature reviews. Urology 2020-11, Vol.17 (11), p.637-642 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 642 |
|---|---|
| container_issue | 11 |
| container_start_page | 637 |
| container_title | Nature reviews. Urology |
| container_volume | 17 |
| creator | Usher-Smith, Juliet Simmons, Rebecca K. Rossi, Sabrina H. Stewart, Grant D. |
| description | Renal cell carcinoma (RCC) incidence is increasing worldwide. A high proportion of individuals are asymptomatic at diagnosis, but RCC has a high mortality rate. These facts suggest that RCC meets some of the criteria for screening, and a new analysis shows that screening for RCC could potentially be cost-effective. Targeted screening of high-risk individuals is likely to be the most cost-effective strategy to maximize the benefits and reduce the harms of screening. However, the size of the benefit of earlier initiation of treatment and the overall cost-effectiveness of screening remains uncertain. The optimal screening modality and target population is also unclear, and uncertainties exist regarding the specification and implementation of a screening programme. Before moving to a fully powered trial of screening, future work should focus on the following: developing and validating accurate risk prediction models; developing non-invasive methods of early RCC detection; establishing the feasibility, public acceptability and potential uptake of screening; establishing the prevalence of RCC and stage distribution of RCC detected by screening; and evaluating the potential harms of screening, including the impact on quality of life, overdiagnosis and over-treatment.
Renal cell carcinoma (RCC) incidence is increasing worldwide. Here, the authors consider the potential benefits and harms of screening for RCC and discuss whether enough evidence is available to begin a clinical trial of RCC screening. |
| doi_str_mv | 10.1038/s41585-020-0363-3 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7610655</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A639929514</galeid><sourcerecordid>A639929514</sourcerecordid><originalsourceid>FETCH-LOGICAL-c568t-6caf0deecea3b96850a27415b819153f677ec8d14620659bfaf247b9815825483</originalsourceid><addsrcrecordid>eNp1kk1r3DAQhkVpaNK0P6CXYiiUXrzRh_V1KYSlXxDoJT0LWR7tKnilVLID-feV2XSTLQ06SOh95p0ZaRB6R_CKYKYuSke44i2muMVMsJa9QGdEct12iuKXhzOhp-h1KTcYC9FJ8QqdMqoExlifodV6zhni1MBdGCA6aFJsissAMcRN41NuqmzHxtkq5jfoxNuxwNuH_Rz9-vrlev29vfr57cf68qp1XKipFc56PAA4sKzXQnFsqazF9opowpkXUoJTA-kExYLr3ltPO9lrVfuhvFPsHH3e-97O_Q4GVyvMdjS3OexsvjfJBnOsxLA1m3RnpCDVkVeDTw8GOf2eoUxmF4qDcbQR0lwM7ZgSUmO-5PrwD3qT5lx7XihJOFVU6kdqY0cwIfpU87rF1FwKpjXVnHSVWv2HqmuAXXApgg_1_ijg45OALdhx2pY0zlNIsRyDZA-6nErJ4A-PQbBZpsHsp8HUaTDLNBhWY94_fcVDxN_vrwDdA6VKcQP5sfXnXf8ADmC70g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471528279</pqid></control><display><type>article</type><title>Current evidence on screening for renal cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Usher-Smith, Juliet ; Simmons, Rebecca K. ; Rossi, Sabrina H. ; Stewart, Grant D.</creator><creatorcontrib>Usher-Smith, Juliet ; Simmons, Rebecca K. ; Rossi, Sabrina H. ; Stewart, Grant D.</creatorcontrib><description>Renal cell carcinoma (RCC) incidence is increasing worldwide. A high proportion of individuals are asymptomatic at diagnosis, but RCC has a high mortality rate. These facts suggest that RCC meets some of the criteria for screening, and a new analysis shows that screening for RCC could potentially be cost-effective. Targeted screening of high-risk individuals is likely to be the most cost-effective strategy to maximize the benefits and reduce the harms of screening. However, the size of the benefit of earlier initiation of treatment and the overall cost-effectiveness of screening remains uncertain. The optimal screening modality and target population is also unclear, and uncertainties exist regarding the specification and implementation of a screening programme. Before moving to a fully powered trial of screening, future work should focus on the following: developing and validating accurate risk prediction models; developing non-invasive methods of early RCC detection; establishing the feasibility, public acceptability and potential uptake of screening; establishing the prevalence of RCC and stage distribution of RCC detected by screening; and evaluating the potential harms of screening, including the impact on quality of life, overdiagnosis and over-treatment.
Renal cell carcinoma (RCC) incidence is increasing worldwide. Here, the authors consider the potential benefits and harms of screening for RCC and discuss whether enough evidence is available to begin a clinical trial of RCC screening.</description><identifier>ISSN: 1759-4812</identifier><identifier>EISSN: 1759-4820</identifier><identifier>DOI: 10.1038/s41585-020-0363-3</identifier><identifier>PMID: 32860009</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4025/2768/1588 ; 692/4028 ; 692/53 ; 692/700/478/2772 ; Cancer ; Carcinoma, Renal cell ; Carcinoma, Renal Cell - diagnosis ; Diagnosis ; Early Detection of Cancer ; Feasibility Studies ; Humans ; Kidney cancer ; Kidney Neoplasms - diagnosis ; Medicine ; Medicine & Public Health ; Overdiagnosis ; Overtreatment ; Perspective ; Quality of Life ; Risk Assessment ; Survival Rate ; Urology</subject><ispartof>Nature reviews. Urology, 2020-11, Vol.17 (11), p.637-642</ispartof><rights>Springer Nature Limited 2020</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>Springer Nature Limited 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c568t-6caf0deecea3b96850a27415b819153f677ec8d14620659bfaf247b9815825483</citedby><cites>FETCH-LOGICAL-c568t-6caf0deecea3b96850a27415b819153f677ec8d14620659bfaf247b9815825483</cites><orcidid>0000-0002-8501-2531 ; 0000-0003-3188-9140 ; 0000-0001-7048-7158</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41585-020-0363-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41585-020-0363-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32860009$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Usher-Smith, Juliet</creatorcontrib><creatorcontrib>Simmons, Rebecca K.</creatorcontrib><creatorcontrib>Rossi, Sabrina H.</creatorcontrib><creatorcontrib>Stewart, Grant D.</creatorcontrib><title>Current evidence on screening for renal cancer</title><title>Nature reviews. Urology</title><addtitle>Nat Rev Urol</addtitle><addtitle>Nat Rev Urol</addtitle><description>Renal cell carcinoma (RCC) incidence is increasing worldwide. A high proportion of individuals are asymptomatic at diagnosis, but RCC has a high mortality rate. These facts suggest that RCC meets some of the criteria for screening, and a new analysis shows that screening for RCC could potentially be cost-effective. Targeted screening of high-risk individuals is likely to be the most cost-effective strategy to maximize the benefits and reduce the harms of screening. However, the size of the benefit of earlier initiation of treatment and the overall cost-effectiveness of screening remains uncertain. The optimal screening modality and target population is also unclear, and uncertainties exist regarding the specification and implementation of a screening programme. Before moving to a fully powered trial of screening, future work should focus on the following: developing and validating accurate risk prediction models; developing non-invasive methods of early RCC detection; establishing the feasibility, public acceptability and potential uptake of screening; establishing the prevalence of RCC and stage distribution of RCC detected by screening; and evaluating the potential harms of screening, including the impact on quality of life, overdiagnosis and over-treatment.
Renal cell carcinoma (RCC) incidence is increasing worldwide. Here, the authors consider the potential benefits and harms of screening for RCC and discuss whether enough evidence is available to begin a clinical trial of RCC screening.</description><subject>692/4025/2768/1588</subject><subject>692/4028</subject><subject>692/53</subject><subject>692/700/478/2772</subject><subject>Cancer</subject><subject>Carcinoma, Renal cell</subject><subject>Carcinoma, Renal Cell - diagnosis</subject><subject>Diagnosis</subject><subject>Early Detection of Cancer</subject><subject>Feasibility Studies</subject><subject>Humans</subject><subject>Kidney cancer</subject><subject>Kidney Neoplasms - diagnosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Overdiagnosis</subject><subject>Overtreatment</subject><subject>Perspective</subject><subject>Quality of Life</subject><subject>Risk Assessment</subject><subject>Survival Rate</subject><subject>Urology</subject><issn>1759-4812</issn><issn>1759-4820</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kk1r3DAQhkVpaNK0P6CXYiiUXrzRh_V1KYSlXxDoJT0LWR7tKnilVLID-feV2XSTLQ06SOh95p0ZaRB6R_CKYKYuSke44i2muMVMsJa9QGdEct12iuKXhzOhp-h1KTcYC9FJ8QqdMqoExlifodV6zhni1MBdGCA6aFJsissAMcRN41NuqmzHxtkq5jfoxNuxwNuH_Rz9-vrlev29vfr57cf68qp1XKipFc56PAA4sKzXQnFsqazF9opowpkXUoJTA-kExYLr3ltPO9lrVfuhvFPsHH3e-97O_Q4GVyvMdjS3OexsvjfJBnOsxLA1m3RnpCDVkVeDTw8GOf2eoUxmF4qDcbQR0lwM7ZgSUmO-5PrwD3qT5lx7XihJOFVU6kdqY0cwIfpU87rF1FwKpjXVnHSVWv2HqmuAXXApgg_1_ijg45OALdhx2pY0zlNIsRyDZA-6nErJ4A-PQbBZpsHsp8HUaTDLNBhWY94_fcVDxN_vrwDdA6VKcQP5sfXnXf8ADmC70g</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Usher-Smith, Juliet</creator><creator>Simmons, Rebecca K.</creator><creator>Rossi, Sabrina H.</creator><creator>Stewart, Grant D.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8501-2531</orcidid><orcidid>https://orcid.org/0000-0003-3188-9140</orcidid><orcidid>https://orcid.org/0000-0001-7048-7158</orcidid></search><sort><creationdate>20201101</creationdate><title>Current evidence on screening for renal cancer</title><author>Usher-Smith, Juliet ; Simmons, Rebecca K. ; Rossi, Sabrina H. ; Stewart, Grant D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c568t-6caf0deecea3b96850a27415b819153f677ec8d14620659bfaf247b9815825483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>692/4025/2768/1588</topic><topic>692/4028</topic><topic>692/53</topic><topic>692/700/478/2772</topic><topic>Cancer</topic><topic>Carcinoma, Renal cell</topic><topic>Carcinoma, Renal Cell - diagnosis</topic><topic>Diagnosis</topic><topic>Early Detection of Cancer</topic><topic>Feasibility Studies</topic><topic>Humans</topic><topic>Kidney cancer</topic><topic>Kidney Neoplasms - diagnosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Overdiagnosis</topic><topic>Overtreatment</topic><topic>Perspective</topic><topic>Quality of Life</topic><topic>Risk Assessment</topic><topic>Survival Rate</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Usher-Smith, Juliet</creatorcontrib><creatorcontrib>Simmons, Rebecca K.</creatorcontrib><creatorcontrib>Rossi, Sabrina H.</creatorcontrib><creatorcontrib>Stewart, Grant D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nature reviews. Urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Usher-Smith, Juliet</au><au>Simmons, Rebecca K.</au><au>Rossi, Sabrina H.</au><au>Stewart, Grant D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current evidence on screening for renal cancer</atitle><jtitle>Nature reviews. Urology</jtitle><stitle>Nat Rev Urol</stitle><addtitle>Nat Rev Urol</addtitle><date>2020-11-01</date><risdate>2020</risdate><volume>17</volume><issue>11</issue><spage>637</spage><epage>642</epage><pages>637-642</pages><issn>1759-4812</issn><eissn>1759-4820</eissn><abstract>Renal cell carcinoma (RCC) incidence is increasing worldwide. A high proportion of individuals are asymptomatic at diagnosis, but RCC has a high mortality rate. These facts suggest that RCC meets some of the criteria for screening, and a new analysis shows that screening for RCC could potentially be cost-effective. Targeted screening of high-risk individuals is likely to be the most cost-effective strategy to maximize the benefits and reduce the harms of screening. However, the size of the benefit of earlier initiation of treatment and the overall cost-effectiveness of screening remains uncertain. The optimal screening modality and target population is also unclear, and uncertainties exist regarding the specification and implementation of a screening programme. Before moving to a fully powered trial of screening, future work should focus on the following: developing and validating accurate risk prediction models; developing non-invasive methods of early RCC detection; establishing the feasibility, public acceptability and potential uptake of screening; establishing the prevalence of RCC and stage distribution of RCC detected by screening; and evaluating the potential harms of screening, including the impact on quality of life, overdiagnosis and over-treatment.
Renal cell carcinoma (RCC) incidence is increasing worldwide. Here, the authors consider the potential benefits and harms of screening for RCC and discuss whether enough evidence is available to begin a clinical trial of RCC screening.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32860009</pmid><doi>10.1038/s41585-020-0363-3</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-8501-2531</orcidid><orcidid>https://orcid.org/0000-0003-3188-9140</orcidid><orcidid>https://orcid.org/0000-0001-7048-7158</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1759-4812 |
| ispartof | Nature reviews. Urology, 2020-11, Vol.17 (11), p.637-642 |
| issn | 1759-4812 1759-4820 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7610655 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | 692/4025/2768/1588 692/4028 692/53 692/700/478/2772 Cancer Carcinoma, Renal cell Carcinoma, Renal Cell - diagnosis Diagnosis Early Detection of Cancer Feasibility Studies Humans Kidney cancer Kidney Neoplasms - diagnosis Medicine Medicine & Public Health Overdiagnosis Overtreatment Perspective Quality of Life Risk Assessment Survival Rate Urology |
| title | Current evidence on screening for renal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A10%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20evidence%20on%20screening%20for%20renal%20cancer&rft.jtitle=Nature%20reviews.%20Urology&rft.au=Usher-Smith,%20Juliet&rft.date=2020-11-01&rft.volume=17&rft.issue=11&rft.spage=637&rft.epage=642&rft.pages=637-642&rft.issn=1759-4812&rft.eissn=1759-4820&rft_id=info:doi/10.1038/s41585-020-0363-3&rft_dat=%3Cgale_pubme%3EA639929514%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471528279&rft_id=info:pmid/32860009&rft_galeid=A639929514&rfr_iscdi=true |